GeneDx (NASDAQ:WGS) CEO Katherine Stueland Sells 25,459 Shares

Key Points

• GeneDx CEO Katherine Stueland sold 25,459 shares on March 4 at an average price of $78.61 for about $2.00 million, reducing her ownership by roughly 39.7% to 38,683 shares.
• Stock and results: WGS traded up ~3.2% to $82 with heavy volume after the sale, and the company recently beat quarterly EPS and revenue estimates ($0.14 EPS vs $0.11 est.; $120.99M revenue vs $120.80M est.).
• Analyst view: Analysts hold a consensus "Moderate Buy" rating with an average price target of about $150.71, despite mixed target revisions from firms like Jefferies, Canaccord and Piper Sandler.

GeneDx Holdings Corp. (NASDAQ:WGS - Get Free Report) CEO Katherine Stueland sold 25,459 shares of the stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $78.61, for a total value of $2,001,331.99. Following the completion of the transaction, the chief executive officer owned 38,683 shares of the company's stock, valued at $3,040,870.63. The trade was a 39.69% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

Katherine Stueland also recently made the following trade(s):

• On Thursday, January 29th, Katherine Stueland sold 1,653 shares of GeneDx stock. The shares were sold at an average price of $94.00, for a total value of $155,382.00.
• On Tuesday, December 16th, Katherine Stueland sold 10,857 shares of GeneDx stock. The stock was sold at an average price of $143.89, for a total value of $1,562,213.73.
• On Tuesday, December 9th, Katherine Stueland sold 3,639 shares of GeneDx stock. The shares were sold at an average price of $159.28, for a total transaction of $579,619.92.

GeneDx Trading Up 3.2%

WGS stock traded up $2.53 during mid-day trading on Thursday, hitting $82.00. 921,499 shares of the company were exchanged, compared to its average volume of 780,593. GeneDx Holdings Corp. has a 12-month low of $55.17 and a 12-month high of $170.87. The firm has a market capitalization of $2.40 billion, a P/E ratio of -109.33 and a beta of 2.03. The business has a fifty day simple moving average of $102.81 and a 200-day simple moving average of $122.71. The company has a quick ratio of 2.34, a current ratio of 2.46 and a debt-to-equity ratio of 0.16.

GeneDx (NASDAQ:WGS - Get Free Report) last issued its quarterly earnings data on Monday, February 23rd. The company reported $0.14 EPS for the quarter, topping the consensus estimate of $0.11 by $0.03. The firm had revenue of $120.99 million for the quarter, compared to analyst estimates of $120.80 million. GeneDx had a negative net margin of 4.92% and a positive return on equity of 14.73%. On average, equities research analysts predict that GeneDx Holdings Corp. will post 0.97 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

WGS has been the topic of a number of recent research reports. Jefferies Financial Group set a $150.00 price target on shares of GeneDx in a research note on Monday, February 23rd. Canaccord Genuity Group increased their target price on shares of GeneDx from $160.00 to $170.00 and gave the stock a "buy" rating in a report on Monday, December 22nd. Piper Sandler reiterated an "overweight" rating and issued a $130.00 price objective (down from $160.00) on shares of GeneDx in a research note on Tuesday, February 24th. BTIG Research cut their price target on GeneDx from $200.00 to $170.00 and set a "buy" rating on the stock in a report on Tuesday, February 24th. Finally, Wall Street Zen cut GeneDx from a "buy" rating to a "hold" rating in a research note on Sunday, February 8th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $150.71.

Institutional Trading of GeneDx

A number of institutional investors have recently bought and sold shares of WGS. Caitong International Asset Management Co. Ltd increased its holdings in shares of GeneDx by 3,704.5% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 837 shares of the company's stock valued at $109,000 after acquiring an additional 815 shares during the last quarter. Invesco Ltd. boosted its holdings in GeneDx by 59.2% in the fourth quarter. Invesco Ltd. now owns 786,466 shares of the company's stock valued at $102,288,000 after purchasing an additional 292,394 shares in the last quarter. Beacon Pointe Advisors LLC purchased a new position in GeneDx in the fourth quarter valued at approximately $208,000. Regal Partners Ltd raised its holdings in GeneDx by 180.0% during the fourth quarter. Regal Partners Ltd now owns 7,000 shares of the company's stock worth $910,000 after purchasing an additional 4,500 shares in the last quarter. Finally, Empowered Funds LLC purchased a new stake in shares of GeneDx during the 4th quarter worth approximately $73,000. 61.72% of the stock is owned by hedge funds and other institutional investors.

About GeneDx

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx's laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.